STOCK TITAN

Alkermes plc - ALKS STOCK NEWS

Welcome to our dedicated news page for Alkermes plc (Ticker: ALKS), a resource for investors and traders seeking the latest updates and insights on Alkermes plc.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Alkermes plc's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Alkermes plc's position in the market.

Rhea-AI Summary
Alkermes plc (Nasdaq: ALKS) to Participate in Fireside Chat at Jefferies London Healthcare Conference on Nov. 14, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.86%
Tags
conferences
-
Rhea-AI Summary
Alkermes plc announced that the Registration Statement on Form 10 filed by Mural Oncology plc was declared effective by the SEC. Alkermes plans to separate its oncology business into Mural Oncology, a new independent company. The separation will be completed on Nov. 15, 2023, with Alkermes shareholders receiving one ordinary share of Mural Oncology for every 10 ordinary shares of Alkermes held. Mural Oncology's shares will be listed on Nasdaq under the ticker symbol 'MURA' starting on Nov. 16, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.45%
Tags
none
-
Rhea-AI Summary
Alkermes, a pharmaceutical company, emphasizes stakeholder engagement and corporate responsibility in their September 2023 Corporate Responsibility Report. They seek to engage with stakeholders to inform their approach to medicine development and commercialization. The company is committed to engagement with shareholders and has taken actions to strengthen their business and governance practices. Alkermes focuses on operating responsibly and integrating ESG pillars into their business.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.49%
Tags
none
Rhea-AI Summary
Alkermes reports Q3 2023 financial results, with revenues of $380.9 million and net sales of proprietary products increasing by approximately 16% YoY. GAAP net income is $47.8 million and non-GAAP net income is $109.5 million. The company reiterates its financial expectations for full-year 2023. The separation of the oncology business is expected to be completed in November 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.39%
Tags
-
Rhea-AI Summary
Alkermes publishes its September 2023 Corporate Responsibility Report, highlighting its commitment to corporate responsibility and sustainability.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.59%
Tags
none
-
Rhea-AI Summary
Alkermes announces preliminary results from a phase 1 study of ALKS 2680 for narcolepsy treatment. Initial data shows significant improvement in sleep latency compared to placebo. ALKS 2680 was well tolerated and supports once-daily dosing. Phase 2 study planned for 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.59%
Tags
Rhea-AI Summary
Alkermes to discuss Q3 financial results and clinical data on ALKS 2680 in conference call and webcast
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.36%
Tags
conferences earnings
-
Rhea-AI Summary
Alkermes proudly announces release of 2023 Corporate Responsibility Report
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.25%
Tags
none
-
Rhea-AI Summary
Mural Oncology to host investor webcast on October 17
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.25%
Tags
conferences
Rhea-AI Summary
Alkermes to present initial clinical proof-of-concept data for ALKS 2680 at World Sleep Congress
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.92%
Tags
conferences clinical trial
Alkermes plc

Nasdaq:ALKS

ALKS Rankings

ALKS Stock Data

4.08B
158.79M
1.26%
109.34%
8.58%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Ireland
Dublin

About ALKS

alkermes plc is a fully integrated, global biopharmaceutical company developing innovative medicines for the treatment of central nervous system (cns) diseases. the company has a diversified commercial product portfolio and a substantial clinical pipeline of product candidates for chronic diseases that include schizophrenia, depression, addiction and multiple sclerosis. headquartered in dublin, ireland, alkermes plc has an r&d center in waltham, massachusetts; a research and manufacturing facility in athlone, ireland; and a manufacturing facility in wilmington, ohio. for more information, please visit alkermes’ website at www.alkermes.com.